Legend Biotech (LEGN) Change in Receivables (2020 - 2026)

Legend Biotech (LEGN) has 7 years of Change in Receivables data on file, last reported at $11.4 million in Q1 2026.

• Quarterly Change in Receivables rose 93.22% year-over-year to $11.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.9 million (up 479.11% YoY) and the FY2024 annual result came in at $93.8 million, up 194.72% from the prior year.
• Change in Receivables slipped to $11.4 million in Q1 2026, from $25.8 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $96.7 million in Q1 2024 to a low of -$99.0 million in Q4 2023.
• A 5-year average of $3.9 million and a median of $218500.0 in 2022 frame the typical range for Change in Receivables.
• Annual changes were most pronounced in 2023 — Change in Receivables plunged 319416.13% — and 2024, when it jumped 284411.76%.
• Tracing LEGN's Change in Receivables over 5 years: stood at -$31000.0 in 2022, then sank by 319416.13% to -$99.0 million in 2023, then surged by 94.36% to -$5.6 million in 2024, then surged by 562.02% to $25.8 million in 2025, then sank by 55.8% to $11.4 million in 2026.
• The last three Change in Receivables figures came in at $11.4 million (Q1 2026), $25.8 million (Q3 2025), and -$26.2 million (Q2 2025), per Business Quant data.